Opens in a new tab

ESCAT v2 Makes Resistance Clinically Actionable

ESMO has updated its international framework for molecular actionability and introduced a parallel evidence scale for resistance biomarkers. The change reflects a simple reality: sequencing reports need to communicate not only what may work, but what the evidence says probably will not.

November 6, 2026
Editorial
ESCAT v2 expands precision oncology beyond actionability by introducing a structured evidence hierarchy for molecular resistance.

IPM Take

Sequencing has become easier than interpretation, and that may now be the more important precision-oncology problem. ESCAT v2 matters because it creates a structured language for both sensitivity and resistance, helping molecular tumour boards distinguish evidence-backed treatment decisions from attractive but speculative matches.

Executive Summary

The updated ESMO Scale for Clinical Actionability of Molecular Targets, ESCAT v2, was published in Annals of Oncology on 21 October. The framework restructures Tier I actionability into proven, inferred and extrapolated categories, incorporates formal tumour-agnostic evaluation through ETAC-S, refines the grading of prospective and real-world evidence, and introduces a new four-level resistance hierarchy ranging from clinically validated resistance that should contraindicate therapy to preclinical or computational evidence suitable only for research.

Why it matters

  • Clinicians: Molecular reports need to communicate evidence strength, not simply list potential drug matches.
  • Diagnostics / pathology: Actionability and resistance can now be classified within one structured framework.
  • Molecular tumour boards: ESCAT v2 gives multidisciplinary teams a more consistent language for complex cases.
  • HTA bodies / payers: Evidence grading can help separate validated precision treatment from speculative off-label use.

The ESCAT v2 paper published in Annals of Oncology addresses a problem created by the success of genomic medicine itself. Modern sequencing can identify dozens or hundreds of alterations, but the existence of a molecular finding does not tell a clinician whether it predicts meaningful treatment benefit, whether the evidence applies across tumour types or whether another alteration makes the proposed therapy less likely to work. Without a hierarchy, more genomic information can produce more ambiguity rather than better treatment.

Version 2 therefore expands the original actionability framework in two important directions. First, it makes the certainty within the highest actionability tier more explicit, distinguishing proven, inferred and extrapolated evidence while maintaining a clear clinical directive when use is justified. Second, and more importantly, it introduces a structured four-level resistance scale. The ESMO explanation of the updated framework describes this as a way of classifying biomarkers associated with reduced or absent treatment benefit, giving clinicians a formal language not only for identifying promising matches but for recognising when a medicine should probably be avoided.

That shift matters for both care and spending. Precision oncology has historically been framed around the positive match: mutation X points toward drug Y. In practice, knowing that drug Y is unlikely to work can be equally valuable because it prevents futile treatment, toxicity and cost. ESCAT v2 cannot solve unequal access to sequencing or targeted therapies, but it can reduce another form of inequality: two patients receiving the same molecular result and being given very different interpretations depending on the institution or tumour board reviewing it. Precision medicine does not only need more data. It needs a disciplined way to say what those data actually justify.

Source & Evidence